Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Research Article

Development and Characterization of Sulfasalazine Cubosomes for Potential Transdermal Drug Delivery

Author(s): Mekha Mathew, Anasuya Patil* and Hemanth G

Volume 13, Issue 2, 2025

Published on: 15 February, 2024

Page: [320 - 327] Pages: 8

DOI: 10.2174/0122117385269522231113041029

open access plus

Abstract

Background: Rheumatoid arthritis is indeed a constant, progressive autoimmune disease that acts on the synovial membrane, distinguished by joint pain, swelling, and tenderness. Sulfasalazine belongs to BCS Class IV having low solubility and low permeability. To overcome the issue and provide a localized effect Cubosomes were chosen for the transdermal drug delivery system.

Objectives: The primary objective of this investigation was to pass on sulfasalazine-loaded cubosomes over the skin to treat rheumatoid arthritis. On the way to overcome this issue of oral sulfasalazine and provide localized effect, Cubosomes were chosen for the transdermal drug delivery system.

Methods: Sulfasalazine-loaded cubosomes were prepared by the top-down method using GMO and Poloxamer 407. Different concentrations of lipid and surfactant were used in the formulation using 32 full factorial designs. The prepared formulations were assessed for p.s, z,p, %EE, FTIR, SEM, in-vitro release, ex-vivo permeation, and deposition studies with pH 7.4 phosphate buffer saline.

Results: The particle size varies between 65 nm to 129 nm, while the negative zeta potential ranged from - 18.8 mV to -24.8 mV. The entrapment efficiency was between 87% and 95%. The formulations' in-vitro drug release was carried out for 12 hours. The optimized formulation showed a controlled release of sulfasalazine and better ex-vivo permeation and deposition properties than sulfasalazine suspension.

Conclusion: Overall study findings support the possibility of applying transdermal sulfasalazineloaded cubosomes to alleviate rheumatoid arthritis.

Keywords: Cubosomes, sulfasalazine, rheumatoid arthritis, glyceryl monooleate, poloxamer 407, transdermal delivery.

[1]
Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Res 2018; 6(1): 15-20.
[http://dx.doi.org/10.1038/s41413-018-0016-9]
[2]
Chuang SY, Lin CH, Huang TH, Fang JY. Lipid-based nanoparticles as a potential delivery approach in the treatment of rheumatoid arthritis. Nanomaterials 2018; 8(1): 42-50.
[http://dx.doi.org/10.3390/nano8010042] [PMID: 29342965]
[3]
Biggioggero M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of rheumatoid arthritis: An evidence-based review and patient selection. Drug Des Devel Ther 2018; 13(4): 57-70.
[http://dx.doi.org/10.2147/DDDT.S150580] [PMID: 30587928]
[4]
Konig MF, Grzes KM, Robinson PC, Pearce EJ. Sulfasalazine: A risk factor for severe COVID-19? Lancet Rheumatol 2022; 4(6): e388-9.
[http://dx.doi.org/10.1016/S2665-9913(22)00067-4] [PMID: 35310293]
[5]
Mushtaq S, Sarkar R. Sulfasalazine in dermatology: A lesser explored drug with broad therapeutic potential. Int J Womens Dermatol 2020; 6(3): 191-8.
[http://dx.doi.org/10.1016/j.ijwd.2020.01.009] [PMID: 32637543]
[6]
Karami Z, Hamidi M. Cubosomes: Remarkable drug delivery potential. Drug Discov Today 2016; 21(5): 789-801.
[http://dx.doi.org/10.1016/j.drudis.2016.01.004] [PMID: 26780385]
[7]
Sherif AG, El Omar H. Cubosomes: Composition, preparation, and drug delivery applications. J Adv Biomed Pharmaceut Sci 2019; 3(20): 1-9.
[8]
Sivadasan D, Sultan MH, Alqahtani SS, Javed S. Cubosomes in drug delivery-a comprehensive review on its structural components, preparation techniques and therapeutic applications. Biomedicines 2023; 11(4): 1114-30.
[http://dx.doi.org/10.3390/biomedicines11041114] [PMID: 37189732]
[9]
Tongying J. The dexamethasone acetate cubosomes as a potential transdermal delivery system for treating skin inflammation. J Drug Deliv Sci Technol 2022; 75(10): 11-21.
[10]
Xinsheng P. Characterization of cubosomes as a targeted and sustained transdermal delivery system for capsaicin. Drug Des Devel Ther 2015; 9(15): 4209-18.
[11]
Verma P, Ahuja M. Cubic liquid crystalline nanoparticles: Optimization and evaluation for ocular delivery of tropicamide. Drug Deliv 2016; 23(8): 3043-54.
[http://dx.doi.org/10.3109/10717544.2016.1143057] [PMID: 26878398]
[12]
Mayank S. Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 23 full-factorial Design. Am Assoc Pharmaceut Sci 2010; 11(2): 489-96.
[13]
Radhakrishnan N. Cubosomes of dapsone enhanced permeation across the skin. J Drug Deliv Sci Technol 2018; 48(18): 75-81.
[14]
Yasir M. Application of UV spectrophotometric method for easy and rapid estimation of sulfasalazine in pharmaceutical formulation (suspension). Pharm Methods 2017; 8(1): 174-7.
[15]
Ananda KC. Design, formulation, in-vitro and ex-vivo evaluation of atazanavir loaded cubosomal gel. Biointerface Res Appl Chem 2021; 11(4): 12037-54.
[16]
Wilson V, Siram K, Rajendran S, Sankar V. Development and evaluation of finasteride loaded ethosomes for targeting to the pilosebaceous unit. Artif Cells Nanomed Biotechnol 2018; 46(8): 1892-901.
[PMID: 29087225]
[17]
Jabar AF. In vitroin vivo correlation from lactide-co-glycolide polymeric dosage forms. Prog Biomater 2014; 3(18): 132-42.
[18]
Sayed S, Abdel-Moteleb M, Amin MM, Khowessah OM. Cubogel as potential platform for glaucoma management. Drug Deliv 2021; 28(1): 293-305.
[http://dx.doi.org/10.1080/10717544.2021.1872740] [PMID: 33509004]
[19]
Salah S, Mahmoud AA, Kamel AO. Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: Ex vivo permeation and in vivo pharmacokinetic studies. Drug Deliv 2017; 24(1): 846-56.
[http://dx.doi.org/10.1080/10717544.2017.1326539] [PMID: 28535740]
[20]
Kumar J. Development of methotrexate-loaded cubosomes with improved skin permeation for the topical treatment of rheumatoid arthritis. Appl Nanosci 2019; 9(2): 1781-96.
[21]
El-Enin HA, AL-Shanbari AH. Nanostructured liquid crystalline formulation as a remarkable new drug delivery system of anti-epileptic drugs for treating children patients. Saudi Pharm J 2018; 26(6): 790-800.
[http://dx.doi.org/10.1016/j.jsps.2018.04.004] [PMID: 30202219]
[22]
Karishma K. Development and characterization of sustained release methotrexate loaded cubosomes for topical delivery in rheumatoid arthritis. Int J Appl Pharmaceut 2020; 12(3): 33-9.
[23]
Anasuya P. Formulation, evaluation and optimization of Piroxicam loaded ethosomes: A Factorial Study. Eur Chem Bull 2023; 12(4): 1740-55.
[24]
Alaa EE. Formulation and evaluation of cubosomes drug delivery system for treatment of glaucoma: Ex-vivo permeation and in-vivo pharmacodynamic study. J Drug Deliv Sci Technol 2019; 52(5): 236-47.
[25]
Shi X, Peng T, Huang Y, et al. Comparative studies on glycerol monooleate- and phytantriol-based cubosomes containing oridonin in vitro and in vivo. Pharm Dev Technol 2017; 22(3): 322-9.
[http://dx.doi.org/10.3109/10837450.2015.1121496] [PMID: 26670780]

© 2025 Bentham Science Publishers | Privacy Policy